# reload+after+2024-01-21 18:43:37.516837
address1§1 Caspian Point
address2§Caspian Way
city§Cardiff
zip§CF10 4DQ
country§United Kingdom
phone§44 29 2048 0180
website§https://www.biodexapharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
fullTimeEmployees§27
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Stephen A. Stamp', 'age': 61, 'title': 'CEO, CFO, Company Secretary & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 302700, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dmitry  Zamoryakhin M.D.', 'age': 43, 'title': 'Chief Scientific Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 301145, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Daniel  Palmer MBA, Ph.D.', 'title': 'Vice President of Technology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nicola  Tuckwell', 'title': 'VP & Head of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Fiona  Sharp', 'title': 'Group Financial Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.786
priceToSalesTrailing12Months§12.577656
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§Biodexa Pharmaceuticals plc
longName§Biodexa Pharmaceuticals Plc
firstTradeDateEpochUtc§1449498600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§77d68f67-48f8-35fb-8abb-8876c307ccfa
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§3.182
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
